Sutanto Henry, Heijman Jordi
Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.
Front Physiol. 2020 Oct 22;11:587709. doi: 10.3389/fphys.2020.587709. eCollection 2020.
The antimalarial drug, chloroquine (CQ), and antimicrobial drug, azithromycin (AZM), have received significant attention during the COVID-19 pandemic. Both drugs can alter cardiac electrophysiology and have been associated with drug-induced arrhythmias. Meanwhile, sympathetic activation is commonly observed during systemic inflammation and oxidative stress (e.g., in SARS-CoV-2 infection) and may influence the electrophysiological effects of CQ and AZM. Here, we investigated the effect of beta-adrenergic stimulation on proarrhythmic properties of CQ and AZM using detailed models of ventricular electrophysiology. Concentration-dependent alterations in ion-channel function were incorporated into the Heijman canine and O'Hara-Rudy human ventricular cardiomyocyte models. Single and combined drug effects on action-potential (AP) properties were analyzed using a population of 1,000 models accommodating inter-individual variability. Sympathetic stimulation was simulated by increasing pacing rate and experimentally validated isoproterenol (ISO)-induced changes in ion-channel function. In the canine ventricular model at 1 Hz pacing, therapeutic doses of CQ and AZM (5 and 20 μM, respectively) individually prolonged AP duration (APD) by 33 and 13%. Their combination produced synergistic APD prolongation (+161%) with incidence of proarrhythmic early afterdepolarizations in 53.5% of models. Increasing the pacing frequency to 2 Hz shortened APD and together with 1 μM ISO counteracted the drug-induced APD prolongation. No afterdepolarizations occurred following increased rate and simulated application of ISO. Similarly, CQ and AZM individually prolonged APD by 43 and 29% in the human ventricular cardiomyocyte model, while their combination prolonged APD by 76% without causing early afterdepolarizations. Consistently, 1 μM ISO at 2 Hz pacing counteracted the drug-induced APD prolongation. Increasing the I window current produced afterdepolarizations, which were exacerbated by ISO. In both models, reduced extracellular K reduced the repolarization reserve and increased drug effects. In conclusion, CQ- and AZM-induced proarrhythmia is promoted by conditions with reduced repolarization reserve. Sympathetic stimulation limits drug-induced APD prolongation, suggesting the potential importance of heart rate and autonomic status monitoring in particular conditions (e.g., COVID-19).
抗疟药物氯喹(CQ)和抗菌药物阿奇霉素(AZM)在新冠疫情期间受到了广泛关注。这两种药物都能改变心脏电生理,且与药物性心律失常有关。同时,在全身炎症和氧化应激期间(如在新冠病毒感染中),交感神经激活普遍存在,可能会影响CQ和AZM的电生理效应。在此,我们使用详细的心室电生理模型研究了β-肾上腺素能刺激对CQ和AZM促心律失常特性的影响。离子通道功能的浓度依赖性改变被纳入Heijman犬心室模型和O'Hara-Rudy人心室心肌细胞模型。使用包含个体间变异性的1000个模型群体分析了单一药物和联合药物对动作电位(AP)特性的影响。通过提高起搏频率模拟交感神经刺激,并通过实验验证异丙肾上腺素(ISO)诱导的离子通道功能变化。在犬心室模型中,以1 Hz起搏时,治疗剂量的CQ和AZM(分别为5和20 μM)单独使动作电位时程(APD)延长了33%和13%。它们的联合使用使APD协同延长(+161%),在53.5%的模型中出现促心律失常的早期后去极化。将起搏频率提高到2 Hz可缩短APD,并与1 μM ISO一起抵消药物诱导的APD延长。在增加频率并模拟应用ISO后未出现后去极化。同样,在人心室心肌细胞模型中,CQ和AZM单独使APD延长了43%和29%,而它们的联合使用使APD延长了76%,且未引起早期后去极化。一致的是,在2 Hz起搏时,1 μM ISO抵消了药物诱导的APD延长。增加I窗电流会产生后去极化,ISO会加剧这种情况。在两个模型中,细胞外钾离子减少会降低复极储备并增强药物作用。总之,复极储备降低的情况会促进CQ和AZM诱导的促心律失常。交感神经刺激会限制药物诱导的APD延长,这表明在特定情况下(如新冠疫情)监测心率和自主神经状态具有潜在重要性。